WEXFORD,
Pa., April 2, 2024 /PRNewswire/ -- Coeptis
Therapeutics Holdings, Inc. (Nasdaq: COEP) ("Coeptis" or "the
Company"), a biopharmaceutical company developing innovative cell
therapy platforms for cancer, is pleased to acknowledge and
congratulate Professor Alexander
Deiters, on receiving the University of
Pittsburgh's 2024 Chancellor's Distinguished Research Award.
This prestigious award honors outstanding individuals whose
scholarly commitments and contributions to research have
significantly advanced their respective fields.
Deiters co-developed a CAR T cell therapy platform called
"SNAP-CAR" that is based on covalent modification of a universal
receptor with adaptor molecules that target these T cells to
tumors.
Alexander
Deiters, chemistry professor in the Kenneth P.
Dietrich School of Arts and Sciences, was honored for his
innovation and interdisciplinary research at the interface of
chemistry and biology, which aims to discover new therapeutic
approaches and improve human health. For example, by discovering
inhibitors of the microRNA pathway and of enzymes involved in phase
II metabolism. Deiters' peers described him as "one of the most
productive research contributors in the field" whose research
program "shows both breadth and depth."
"We commend Deiters for his outstanding dedication and
invaluable contributions to the development of SNAP-CAR T
technology," said Dave Mehalick,
President and CEO of Coeptis Therapeutics. "We are excited to help
advance the groundbreaking SNAP-CAR technology as potential
therapies for a range of conditions within the fields of oncology
and autoimmune disorders, where significant treatment gaps persist.
Given its vast potential, these technologies have the opportunity
to revolutionize the treatment paradigm across multiple healthcare
sectors."
The Company recently expanded its exclusive license agreement
with the University of Pittsburgh to
include the SNAP-CAR technology platform in natural killer (NK)
cells and autoimmune indications. Recent research suggests that
CD19-targeting chimeric antigen receptor CAR T cells, which have
proven to be highly efficient in B cell malignancies, can also
target autoreactive B cells that trigger autoimmune diseases.
About Coeptis Therapeutics Holdings, Inc.
Coeptis
Therapeutics Holdings, Inc., together with its
subsidiaries including Coeptis Therapeutics,
Inc. and Coeptis Pharmaceuticals,
Inc., (collectively "Coeptis"), is a biopharmaceutical
company developing innovative cell therapy platforms for cancer,
autoimmune, and infectious diseases that have the potential to
disrupt conventional treatment paradigms and improve patient
outcomes. Coeptis' product portfolio and rights are highlighted by
assets licensed from Deverra Therapeutics, including an allogeneic
cellular immunotherapy platform and DVX201, a clinical-stage,
unmodified natural killer cell therapy technology. Additionally,
Coeptis is developing a universal, multi-antigen CAR T technology
licensed from the University of
Pittsburgh (SNAP-CAR), and the GEAR cell therapy and
companion diagnostic platforms, which Coeptis is
developing with VyGen-Bio and leading medical researchers at
the Karolinska Institutet. Coeptis' business model is designed
around maximizing the value of its current product portfolio and
rights through in-license agreements, out-license agreements and
co-development relationships, as well as entering into strategic
partnerships to expand its product rights and offerings,
specifically those targeting cancer and infectious diseases. The
Company is headquartered in Wexford, PA. For more information
on Coeptis visit https://coeptistx.com/.
Cautionary Note Regarding Forward-Looking Statements
This press release and statements of our management made in
connection therewith contain or may contain "forward-looking
statements" (as defined in Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended). Forward-looking statements include statements
concerning our plans, objectives, goals, strategies, future events
or performance, and underlying assumptions, and other statements
that are other than statements of historical facts. When we use
words such as "may," "will," "intend," "should," "believe,"
"expect," "anticipate," "project," "estimate" or similar
expressions that do not relate solely to historical matters, we are
making forward-looking statements. Forward-looking statements are
not a guarantee of future performance and involve significant risks
and uncertainties that may cause the actual results to differ
materially and perhaps substantially from our expectations
discussed in the forward-looking statements. Factors that may cause
such differences include but are not limited to: (1) the inability
to maintain the listing of the Company's securities on the Nasdaq
Capital Market; (2) the risk that the integration of the Deverra
licensed assets will disrupt current plans and operations of the
Company; (3) the inability to recognize the anticipated benefits of
the newly-licensed assets, which may be affected by, among other
things, competition, the ability of the Company to grow and manage
growth economically and hire and retain key employees; (4) the
risks that the Company's products in development or the
newly-licensed assets fail clinical trials or are not approved by
the U.S. Food and Drug Administration or other applicable
regulatory authorities; (5) costs related to integrating the
newly-licensed Deverra assets and pursuing the contemplated asset
development paths; (6) changes in applicable laws or regulations;
(7) the possibility that the Company may be adversely affected by
other economic, business, and/or competitive factors; and (8) the
impact of the global COVID-19 pandemic on any of the foregoing
risks and other risks and uncertainties identified in the Company's
filings with the Securities and Exchange Commission (the "SEC").
The foregoing list of factors is not exclusive. All forward-looking
statements are subject to significant uncertainties and risks
including, but not limited, to those risks contained or to be
contained in reports and other filings filed by the Company with
the SEC. For these reasons, among others, investors are cautioned
not to place undue reliance upon any forward-looking statements in
this press release. Additional factors are discussed in the
Company's filings made or to be made with the SEC, which are
available for review at www.sec.gov. We undertake no
obligation to publicly revise these forward-looking statements to
reflect events or circumstances that arise after the date hereof
unless required by applicable laws, regulations, or rules.
CONTACTS
Coeptis Therapeutics, Inc.
invest@coeptistx.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/coeptis-therapeutics-congratulates-alexander-deiters-professor-at-the-university-of-pittsburgh-on-receiving-the-2024-chancellors-distinguished-research-award-302105132.html
SOURCE Coeptis Therapeutics, Inc.